Daratumumab Immunopolymersome‐Enabled Safe and CD38‐Targeted Chemotherapy and Depletion of Multiple Myeloma

Nanoparticle-Mediated Co-Delivery of Notch-1 Antibodies and ABT-737 as a Potent Treatment Strategy for Triple-Negative Breast Cancer

(2020) Danielle M. Valcourt et al.   ACS Nano

Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management

(2020) S. Vincent Rajkumar   AMERICAN JOURNAL OF HEMATOLOGY

CD44-targeted vesicles encapsulating granzyme B as artificial killer cells for potent inhibition of human multiple myeloma in mice

(2020) Yinan Zhong et al.   JOURNAL OF CONTROLLED RELEASE

Acute lymphoblastic leukaemia

(2020) Florent Malard et al.   LANCET

Anti-CD38 monoclonal antibodies in multiple myeloma: another cook in the kitchen?

(2020) Mattia D'Agostino et al.   Lancet Haematology

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

(2020) Meletios Dimopoulos et al.   LANCET

Multiple Myeloma Associated Bone Disease

(2020) Stine Rasch et al.   Cancers

GE11 peptide-installed chimaeric polymersomes tailor-made for high-efficiency EGFR-targeted protein therapy of orthotopic hepatocellular carcinoma

(2020) Cheng Zhou et al.   Acta Biomaterialia

When liposomes met antibodies: Drug delivery and beyond

(2020) Jiaxing Di et al.   ADVANCED DRUG DELIVERY REVIEWS

Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against Myeloma

(2019) Yung-Hsing Huang et al.   Cancers

The Mechanism Of Action Of The Anti-CD38 Monoclonal Antibody Isatuximab In Multiple Myelmoa

(2019) Laura Moreno et al.   CLINICAL CANCER RESEARCH

Myelofibrosis osteoclasts are clonal and functionally impaired

(2019) Ivo Veletic et al.   BLOOD

Daratumumab in multiple myeloma

(2019) Ajay K. Nooka et al.   CANCER

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

(2019) Thierry Facon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models

(2019) Walid S. Kamoun et al.   Nature Biomedical Engineering

Survey of Clinical Translation of Cancer Nanomedicines—Lessons Learned from Successes and Failures

(2019) Hongliang He et al.   ACCOUNTS OF CHEMICAL RESEARCH

CD44‐Specific A6 Short Peptide Boosts Targetability and Anticancer Efficacy of Polymersomal Epirubicin to Orthotopic Human Multiple Myeloma

(2019) Wenxing Gu et al.   ADVANCED MATERIALS

Antibody–drug conjugates for cancer

(2019) Cindy H Chau et al.   LANCET

Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives

(2019) Alessandra Romano et al.   Frontiers in Oncology

Herceptin-conjugated paclitaxel loaded PCL-PEG worm-like nanocrystal micelles for the combinatorial treatment of HER2-positive breast cancer

(2019) Jiahui Peng et al.   BIOMATERIALS

Protein Toxin Chaperoned by LRP-1-Targeted Virus-Mimicking Vesicles Induces High-Efficiency Glioblastoma Therapy In Vivo

(2018) Yu Jiang et al.   ADVANCED MATERIALS

Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma

(2018) Pilar de la Puente et al.   JOURNAL OF CONTROLLED RELEASE

Immunoliposomes in clinical oncology: State of the art and future perspectives

(2018) María Merino et al.   JOURNAL OF CONTROLLED RELEASE

The multiple myelomas — current concepts in cytogenetic classification and therapy

(2018) Shaji K. Kumar et al.   Nature Reviews Clinical Oncology

Animal models of monoclonal immunoglobulin-related renal diseases

(2018) Christophe Sirac et al.   Nature Reviews Nephrology

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

(2018) María-Victoria Mateos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Radionuclides transform chemotherapeutics into phototherapeutics for precise treatment of disseminated cancer

(2018) Nalinikanth Kotagiri et al.   Nature Communications

Progress and challenges towards targeted delivery of cancer therapeutics

(2018) Daniel Rosenblum et al.   Nature Communications

EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental

(2018) Mrinal M. Patnaik et al.   Blood Cancer Journal

Global Burden of Multiple Myeloma

(2018) Andrew J. Cowan et al.   JAMA Oncology

Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma

(2018) Zhaoxin Gu et al.   Acta Biomaterialia

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study

(2018) Pamela Munster et al.   BRITISH JOURNAL OF CANCER

Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy

(2017) Hengfeng Yuan et al.   Nature Nanotechnology

Next generation antibody drugs: pursuit of the 'high-hanging fruit'

(2017) Paul J. Carter et al.   NATURE REVIEWS DRUG DISCOVERY

Strategies and challenges for the next generation of antibody–drug conjugates

(2017) Alain Beck et al.   NATURE REVIEWS DRUG DISCOVERY

Multiple Myeloma and Bone: The Fatal Interaction

(2017) Silvia Marino et al.   Cold Spring Harbor Perspectives in Medicine

Emerging Roles of Osteoclasts in the Modulation of Bone Microenvironment and Immune Suppression in Multiple Myeloma

(2017) Anna Mansour et al.   Frontiers in Immunology

Efficient and Targeted Suppression of Human Lung Tumor Xenografts in Mice with Methotrexate Sodium Encapsulated in All-Function-in-One Chimeric Polymersomes

(2016) Weijing Yang et al.   ADVANCED MATERIALS

Engineered Nanoplatelets for Enhanced Treatment of Multiple Myeloma and Thrombus

(2016) Quanyin Hu et al.   ADVANCED MATERIALS

Bone marrow infiltration by multiple myeloma causes anemia by reversible disruption of erythropoiesis

(2016) Anass Bouchnita et al.   AMERICAN JOURNAL OF HEMATOLOGY

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

(2016) Inger S. Nijhof et al.   BLOOD

Immune Therapies in Multiple Myeloma

(2016) Shaji K. Kumar et al.   CLINICAL CANCER RESEARCH

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma

(2016) Larysa Sanchez et al.   Journal of Hematology & Oncology

Daratumumab in multiple myeloma

(2016) S Vincent Rajkumar   LANCET

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

(2016) Sagar Lonial et al.   LANCET

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

(2016) Shaji Kumar et al.   LANCET ONCOLOGY

VEGF- and VEGFR2-Targeted Liposomes for Cisplatin Delivery to Glioma Cells

(2016) Sergey A. Shein et al.   MOLECULAR PHARMACEUTICS

Efficacy and Safety of Vincristine Sulfate Liposome Injection in the Treatment of Adult Acute Lymphocytic Leukemia

(2016) Dan Douer   ONCOLOGIST

Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer

(2015) Sara Zalba et al.   JOURNAL OF CONTROLLED RELEASE

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

(2015) Henk M. Lokhorst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma

(2015) R Khan et al.   LEUKEMIA

Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo

(2014) Jonathan D. Ashley et al.   JOURNAL OF CONTROLLED RELEASE

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

(2014) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Multifunctional Nanoparticles as Nanocarrier for Vincristine Sulfate Delivery To Overcome Tumor Multidrug Resistance

(2014) Yuan Wang et al.   MOLECULAR PHARMACEUTICS

Engineered nanomedicine for myeloma and bone microenvironment targeting

(2014) A. Swami et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Suppression of colorectal cancer subcutaneous xenograft and experimental lung metastasis using nanoparticle-mediated drug delivery to tumor neovasculature

(2013) Chao Wang et al.   BIOMATERIALS

Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine

(2012) Jeffrey A. Silverman et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study

(2012) Christoph Mamot et al.   LANCET ONCOLOGY

Multifunctional nanoassemblies for vincristine sulfate delivery to overcome multidrug resistance by escaping P-glycoprotein mediated efflux

(2011) Peng Zhang et al.   BIOMATERIALS

Advances in the Biology and Treatment of Bone Disease in Multiple Myeloma

(2011) Noopur Raje et al.   CLINICAL CANCER RESEARCH